These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Beta 2 microglobulin].
    Author: Clément F.
    Journal: Schweiz Med Wochenschr; 1983 Jun 11; 113(23):838-43. PubMed ID: 6192496.
    Abstract:
    Serum beta 2 microglobulin (beta 2 mu) level was determined in 157 patients followed up for 1 to 38 months. In 42 patients with nonremissional lymphoproliferative malignancies, the observed values (mean 4.35 +/- 2.24 mg/l) were much higher than the beta 2 mu levels obtained either in the 37 healthy subjects (mean 1.86 +/- 0.30 mg/l) or in the 39 patients with various nonmalignant diseases (mean 2.68 +/- 1.76 mg/l). However, for diagnostic purposes serum beta 2 mu level determination is still of very limited value: if the beta 2 mu level is below 2.50 mg/l, the beginning of a hematologic malignancy cannot be excluded; beta 2 mu levels between 2.50 and 5.00 mg/l are observed, in most cases, with lymphoproliferative or myeloproliferative disorders, but these values are also often found in various diseases, particularly of viral or autoimmunological etiology; a serum beta 2 mu level above 5.00 mg/l was obtained only in lymphoproliferative malignancies and in one case of "acquired immuno deficiency syndrome" (AIDS) in a homosexual male. Serum beta 2 mu determination is of chief advantage in follow-up of Hodgkin's disease, of non-Hodgkin malignant lymphoma, of chronic lymphocytic leukemia and of multiple myeloma either during treatment or in remission.
    [Abstract] [Full Text] [Related] [New Search]